Experimental Infection Using Mouse-Adapted Influenza B Virus in a Mouse Model
Elena Prokopyeva,
Olga Kurskaya,
Ivan Sobolev,
Mariia Solomatina,
Tatyana Murashkina,
Anastasia Suvorova,
Alexander Alekseev,
Daria Danilenko,
Andrey Komissarov,
Artem Fadeev,
Edward Ramsay,
Alexander Shestopalov,
Alexander Dygai,
Kirill Sharshov
Affiliations
Elena Prokopyeva
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Olga Kurskaya
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Ivan Sobolev
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Mariia Solomatina
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Tatyana Murashkina
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Anastasia Suvorova
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Alexander Alekseev
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Daria Danilenko
Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia
Andrey Komissarov
Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia
Artem Fadeev
Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia
Edward Ramsay
Department of Etiology and Epidemiology, Smorodintsev Research Institute of Influenza, 197376 Saint Petersburg, Russia
Alexander Shestopalov
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Alexander Dygai
Goldberg Research Institute of Pharmacology and Regenerative Medicine Clinic, 634009 Tomsk, Russia
Kirill Sharshov
Department of Development and Testing of Pharmacological Agents, Federal Research Center of Fundamental and Translational Medicine, 630117 Novosibirsk, Russia
Every year, influenza B viruses (IBVs) contribute to annual illness, and infection can lead to serious respiratory disease among humans. More attention is needed in several areas, such as increasing virulence or pathogenicity of circulating B viruses and developing vaccines against current influenza. Since preclinical trials of anti-influenza drugs are mainly conducted in mice, we developed an appropriate infection model, using an antigenically-relevant IBV strain, for furtherance of anti-influenza drug testing and influenza vaccine protective efficacy analysis. A Victoria lineage (clade 1A) IBV was serially passaged 17 times in BALB/c mice, and adaptive amino acid substitutions were found in hemagglutinin (HA) (T214I) and neuraminidase (NA) (D432N). By electron microscopy, spherical and elliptical IBV forms were noted. Light microscopy showed that mouse-adapted IBVs caused influenza pneumonia on day 6 post inoculation. We evaluated the illness pathogenicity, viral load, and histopathological features of mouse-adapted IBVs and estimated anti-influenza drugs and vaccine efficiency in vitro and in vivo. Assessment of an investigational anti-influenza drug (oseltamivir ethoxysuccinate) and an influenza vaccine (Ultrix®, SPBNIIVS, Saint Petersburg, Russia) showed effectiveness against the mouse-adapted influenza B virus.
